Anti-BDCA2 Antibody Meets Primary Endpoint in Phase 2 CLE TrialIn the phase 2 study, improvements in the CLASI-A scores were seen in patients randomly assigned to subcutaneous litifilimab. Medscape Medical Newsadminagosto 5, 2022Uncategorized In the phase 2 study, improvements in the CLASI-A scores were seen in patients randomly assigned to subcutaneous litifilimab. Medscape Medical News